The future of cancer treatment is targeted and precise. And the future is now. Ilumira, SHINE’s non-carrier-added lutetium-177 (n.c.a. Lu-177), is the true power behind smarter cancer therapies. It’s a radioactive agent that, when paired with a cancer-seeking molecule, offers a new level of precision in fighting cancer. Ilumira's ability to precisely target cancer cells is paving the way for a brighter future where treatments are more effective and less harmful.
Ilumira works together with cancer-seeking molecules. The drug smartly delivers the isotope to cancer and its metastases. The isotope emits short-range radiation that selectively destroys cancer cells while sparing healthy tissue. Ilumira is already making a difference in cancer care globally, offering a more targeted and potentially gentler approach to fighting the disease.
Ilumira, our n.c.a. Lu-177, is produced in our U.S. facility, adhering to strict Good Manufacturing Practices (cGMP) and it meets or exceeds all European pharmacopeia monograph for lutetium. We submitted a Drug Master File to the U.S. FDA in 2022. We will expand production capabilities with our large-scale facility, Cassiopeia, coming online soon.
We’re working on becoming the only vertically integrated manufacturer of lutetium-177 in the world. This means we're not just producing Ilumira -- we're also taking control of the entire process, from enriching the raw material (ytterbium-176) to irradiating it and refining the final product to meet customer specifications. This bold initiative aims to eliminate reliance on external nuclear reactors, ensuring a consistent and reliable supply of Lu-177 for the global market.
We stand apart from other fusion companies because we have commercialized fusion today and we are scaling our technology. During each of our four phases, we’re perfecting core competencies needed for commercially viable fusion, producing useful products, building shareholder value, and reinvesting in future growth.
Join us and be part of the solution.
